IgG4-related disease is a multiorgan, relapsing, fibroinflammatory, immune-mediated disorder with no approved therapy. Inebilizumab targets and depletes CD19+ B cells and may be effective for ...

IgG4-related disease (IgG4-RD) is a rare autoimmune disease. A study published in The New England Journal of Medicine by the ...

Discover a trial that included 135 adults, randomly assigned to receive either inebilizumab or a placebo for a 52-week ...

Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

The systemic disease of which AIP is a part has been called IgG4-related systemic diseases. AIP mimics pancreatic cancer and it is critically important to distinguish between the two diseases.

Discover how inebilizumab reduces flares and improves remission rates in IgG4-related disease in this phase 3 clinical trial.

An international, Phase III clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare ...

Dr. Stone said, "A crucial finding for people living with IgG4-RD now has been the efficacy in disease control exerted by B cell depletion. I'm enthusiastic now not only about the possibility of ...

For patients with immunoglobulin G (IgG)4-related disease, inebilizumab reduces the risk for flares and increases the ...